Dipyridamole-acetylsalicylic acid after aortic valve replacement resulted in thrombo-embolic episodes in 11 of 64 patients (17.2%) over 9 months, leading to a resumption of dicumarol.
Cohort
Dicumarol anticoagulation poved very effective in the prevention of thromboembolic complications after aortic valve replacement with the Björk-Shiley tilting disc valve. We have, however, encountered six late deaths because of massive cerebral hemorrhage, which represent 3% of the patients who were maintained on dicumarol medication at that time. This unacceptable mortality prompted us to introduce two programmes, one without anticoagulation and another one with dipyridamole-acetylsalicylic acid. Furthermore, dicumarol was terminated in patients with haemorrhagic episodes, instable anticoagulation, pregnancy, and in those reguiring surgery. The results were disappointing, however, and the majority of the patients involved were therefore put on dicumarol medication. Eleven of the 64 consecutive patients taking dipyridamole - acetylsalicylic acid had thrombo-embolic episodes during a mean follow-up period of 9 months...
Björk et al. (Wed,) conducted a cohort in Aortic valve replacement with the Björk-Shiley tilting disc valve. Dipyridamole-acetylsalicylic acid vs. Dicumarol was evaluated on Thrombo-embolic episodes. Dipyridamole-acetylsalicylic acid after aortic valve replacement resulted in thrombo-embolic episodes in 11 of 64 patients (17.2%) over 9 months, leading to a resumption of dicumarol.